Previous 10 | Next 10 |
Viral immunotherapies company Oncorus (NASDAQ:ONCR) said on Tuesday that it entered a loan and security agreement with K2 HealthVentures, a healthcare focused specialty finance company. Agreement provides Oncorus with up to $45M in multiple tranches upon the achievement of certain m...
-Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use of proceeds intended to support completion of a GMP-compliant manufacturing facility in Andover, MA and the clinical development of its IV administered vRNA/LNP product candidate, ...
Plantronics POLY +49% HP to acquire Poly for $40/share for enhancing Peripherals and workforce solutions businesses. Kaixin Auto KXIN +42% on intention order for 20K electric vehicles. DatChat (DATS) +34% to launch metaverse advertising and NFT monetization platform. ...
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will p...
CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will p...
Oncorus press release (NASDAQ:ONCR): Q4 GAAP EPS of -$0.77 misses by $0.09. Cash and cash equivalents and investments totaled $123.9 million as of December 31, 2021 compared to $130.3 million as of December 31, 2020 For further details see: Oncorus GAAP EPS of -$0.77 misses by $0.09
Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021 Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-...
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the promotion of John Goldberg, M.D. to Chief Medical Officer. Dr. Goldberg joined Oncor...
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will pa...
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will pa...
News, Short Squeeze, Breakout and More Instantly...
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...